Stay updated on Pembrolizumab and Binimetinib in TNBC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab and Binimetinib in TNBC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab and Binimetinib in TNBC Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-14T01:40:26.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents an update in the maximum tolerated dose of binimetinib in combination with pembrolizumab for treating patients with triple negative breast cancer.
    Difference
    0.1%
    Check dated 2024-06-06T15:43:47.000Z thumbnail image
  7. Check
    23 days ago
    Change Detected
    Summary
    The change on the webpage represents an update in the Participation Criteria section, specifically focusing on eligibility criteria for researchers looking for individuals with specific health conditions or prior treatments related to breast adenocarcinoma. The change emphasizes the criteria for inclusion, such as age, histological confirmation, hormone receptor status, and prior lines of treatment, among others.
    Difference
    57%
    Check dated 2024-05-23T21:42:14.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.6%
    Check dated 2024-04-30T22:52:18.000Z thumbnail image

Stay in the know with updates to Pembrolizumab and Binimetinib in TNBC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Binimetinib in TNBC Clinical Trial page.